110 related articles for article (PubMed ID: 11899419)
1. Commentary on "A review of vinorelbine in the treatment of breast cancer".
Ibrahim NK
Clin Breast Cancer; 2001 Oct; 2(3):236. PubMed ID: 11899419
[No Abstract] [Full Text] [Related]
2. [Therapeutic effects of vinorelbine-based chemotherapy--retrospective study of 65 patients with metastatic or relapsed breast cancer].
Watanabe K; Otake T; Yasuda M; Takenoshita S
Gan To Kagaku Ryoho; 2010 Jan; 37(1):51-6. PubMed ID: 20087032
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.
Mano M
Cancer Treat Rev; 2006 Apr; 32(2):106-18. PubMed ID: 16473470
[TBL] [Abstract][Full Text] [Related]
5. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Kubota K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
[TBL] [Abstract][Full Text] [Related]
7. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
8. Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.
Iorfida M; Bagnardi V; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Intra M; Minchella I; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2010 Apr; 19(2):128-32. PubMed ID: 20117001
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
[No Abstract] [Full Text] [Related]
10. A review of vinorelbine in the treatment of breast cancer.
Domenech GH; Vogel CL
Clin Breast Cancer; 2001 Jul; 2(2):113-28. PubMed ID: 11899783
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
Lewis R; Bagnall AM; King S; Woolacott N; Forbes C; Shirran L; Duffy S; Kleijnen J; ter Riet G; Riemsma R
Health Technol Assess; 2002; 6(14):1-269. PubMed ID: 12583816
[No Abstract] [Full Text] [Related]
12. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Burstein HJ; Kuter I; Campos SM; Gelman RS; Tribou L; Parker LM; Manola J; Younger J; Matulonis U; Bunnell CA; Partridge AH; Richardson PG; Clarke K; Shulman LN; Winer EP
J Clin Oncol; 2001 May; 19(10):2722-30. PubMed ID: 11352965
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine--a clinical review.
Gregory RK; Smith IE
Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
[No Abstract] [Full Text] [Related]
14. [A pilot study of trastuzumab and vinorelbine-combined therapy for metastatic breast cancer].
Onishi I; Tsugawa K; Nakamura M; Nishimura G; Fujimura T; Taniya T; Kayahara M; Shimizu K; Ohta T; Miwa K
Gan To Kagaku Ryoho; 2004 May; 31(5):743-6. PubMed ID: 15170984
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
[TBL] [Abstract][Full Text] [Related]
18. [A case of recurrent breast cancer responding to vinorelbine/trastuzumab combination therapy].
Fujisawa M; Uomori T; Takehara K; Mitsugi Y; Yoshino K; Okumura M; Machida M; Kitabatake T; Ishibiki Y; Kojima K; Ogura K; Matsumoto T
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2631-5. PubMed ID: 20009469
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
20. Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine.
Wong ZW; Phillips SJ; Ellis MJ
Breast J; 2004; 10(1):54-6. PubMed ID: 14717761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
